Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Prothena Corporation plcNASDAQ: PRTA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow turns positive

Q1 FY2026 operating cash flow was $28.88M, compared with -$53.36M a year earlier. Trailing-twelve-month operating cash flow was -$81.34M. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Operating cash flow amounted to 1689.2% of revenue in FY2025, up 1578.2 pp from a year earlier.
  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly operating cash flow holds near $28.88M or moves back toward the trailing-twelve-month quarterly average of -$20.34M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.88M+223.9% QoQ
Last fiscal yearDec 2025
-$163.58M+9.0% YoY
LTMMar 2026
-$81.34M-37.6% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.1%——
1 year+9.0%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(163.58M) USD
Year-over-year change
-9.0%

Operating Cash Flow vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.6% is the 9th highest of 10, against a peer median of +3.0%.
  • Operating cash flow amounts to 140.4% of revenue for PRTA, versus a peer median of 1936.8%.
PRTA Competitors
Operating Cash Flow for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$2.88B USD+36.0%+16.8%28.9%
DNLIDenali Therapeutics Inc.LTM Jun 2026$434.04M USD+24.1%+19.0%12043.3%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M USD-3.0%+21.6%—
ANNXAnnexon, Inc.LTM Mar 2026$183.1M USD+31.0%+17.0%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$105.55M USD+3.0%+48.7%—
PRTAProthena Corporation plcLTM Mar 2026$81.34M USD-37.6%+14.6%140.4%
ACIUAC Immune S.A.LTM Dec 2025CHF 69.2M CHF-205.1%-3.5%1936.8%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$42M USD+77.3%+7.1%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$34.08M USD-4.3%+17.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$20.25M USD-34.9%+9.9%—
Peer median (excluding PRTA) —+3.0%+17.0%1936.8%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.